Massachusetts Financial Services Co. MA purchased a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 481,679 shares of the company's stock, valued at approximately $13,111,000. Massachusetts Financial Services Co. MA owned 0.46% of Metsera as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of MTSR. New York State Common Retirement Fund purchased a new stake in shares of Metsera during the first quarter worth $131,000. Bank of New York Mellon Corp acquired a new position in shares of Metsera during the first quarter worth $884,000. Finally, Alphabet Inc. acquired a new position in shares of Metsera during the first quarter worth $135,059,000.
Analyst Ratings Changes
MTSR has been the subject of a number of analyst reports. Wells Fargo & Company initiated coverage on shares of Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 target price for the company. Guggenheim upped their price objective on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a research note on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Metsera currently has an average rating of "Buy" and a consensus target price of $55.00.
View Our Latest Stock Analysis on MTSR
Metsera Stock Performance
Shares of MTSR traded up $0.54 during mid-day trading on Wednesday, hitting $39.99. 839,704 shares of the company's stock were exchanged, compared to its average volume of 748,355. Metsera Inc. has a fifty-two week low of $12.30 and a fifty-two week high of $47.40. The company has a 50 day simple moving average of $31.34.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Metsera Profile
(
Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
